Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
about
Pathophysiology of the neurovascular unit: disease cause or consequence?Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Structural Neuroimaging of the Medial Temporal Lobe in Alzheimer's Disease Clinical Trials.Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP miceDoubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation.Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunizationA novel recombinant 6Aβ15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer's disease-like pathology, cognitive decline and synaptic loss in aged 3 × Tg-AD mice.Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen.Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice.Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine.Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer's disease model.Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease.Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits.Current understanding of the glial response to disorders of the aging CNS.Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's diseaseActive immunization therapies for Parkinson's disease and multiple system atrophy.T-cell epitope-dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice.Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients.Mechanical Dilution of Beta-amyloid Peptide and Phosphorylated Tau Protein in Alzheimer's Disease: Too Simple to be True?Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization.Structural characterization by NMR of a double phosphorylated chimeric peptide vaccine for treatment of Alzheimer's disease.Association between naturally occurring antiamyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease.Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer's Disease.
P2860
Q27690845-633EB30F-BE40-4128-9D4C-7E949B52F320Q30578913-DCAA14A1-B7BA-4672-899B-9B8A203F544CQ30996733-965704EB-A5FE-41C0-9E28-835213BD0370Q34948575-11BEC64D-0C46-4175-9C34-0EAD806933E4Q35826638-74CE0C68-13A0-4877-885F-F16292B0A4C1Q36644869-B6BFE027-0D11-4F9D-AD6B-FB7E3A4ACF9BQ36964826-E2CE0893-AF2E-4CD7-8EE3-0E85231782E7Q37014400-1A536633-86FC-488B-AAFE-2C3565756633Q37042410-27B6F962-ABB1-4CB6-909E-59807572EBD0Q37473219-3184A04D-6B9F-471F-A050-B218A20781EDQ37688368-B3E9E71A-2E5B-46C5-BA12-26BD032D8C2FQ37958200-0F799BF3-FBFA-4E22-9E89-9F88E720ADDBQ37999105-6D82C6D4-A366-4601-8990-C97674C9D08EQ38015354-7F78C50D-57EA-4259-9E0A-24D635C70931Q38079317-E36C706E-BFBE-4946-BEE2-56500DDB92BAQ38172335-217A796E-09D9-4D82-A1B5-9265F1D0F03DQ38564102-C51443C4-5EBE-4804-A033-E7204F8DEE6AQ39409037-8B2871E6-B624-43AD-BBC8-880D2C26CBC8Q39639949-91DFD784-3EEC-43ED-A002-AF654BC87426Q41997807-65A92ED8-72B4-4C89-9E42-5E6F43870778Q44833066-CED31F13-7B23-4687-97EA-19A111E55006Q51035193-5EA54D42-A7A2-4B9C-A058-E09C6DA835C6Q53057411-5E006ACC-6B2E-4B4A-88EC-E06B535FB797Q53513690-41F41133-366C-4A51-9FE3-5C19C4D5CCB1
P2860
Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
@en
Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
@nl
type
label
Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
@en
Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
@nl
prefLabel
Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
@en
Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
@nl
P2093
P1476
Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials
@en
P2093
Alfonso López Muñiz
Jose A Vega
Marta Martínez-Rivera
P304
P356
10.2174/138161211795164112
P577
2011-01-01T00:00:00Z